Surrozen, Inc./DE Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share
Surrozen, Inc./DE (SRZN) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share of -$2.21 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-28.
Discontinued › Income Statement
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare · last filed 2022-03-28
- Surrozen, Inc./DE income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2021 was -$2.21.
- Surrozen, Inc./DE income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2020 was -$2.05.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 12 month |
|---|---|
| 2021-12-31 | -$2.21 10-K · filed 2022-03-28 |
| 2020-12-31 | -$2.05 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |